1
|
Ozdede A, Güner S, Ozcifci G, Yurttas B, Toker Dincer Z, Atli Z, Uygunoglu U, Durmaz E, Ucar D, Ugurlu S, Saip S, Tabak ÖF, Hamuryudan V, Seyahi E. POS1255 SAFETY OF THE PFIZER/BIONTECH AND SINOVAC/CORONAVAC VACCINES AMONG PATIENTS WITH BEHCET’S SYNDROME AND FAMILIAL MEDITERRANEAN FEVER. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSince first emerged in December 2019, the COVID-19 pandemic has resulted in a death toll surpassing 5.5 million worldwide and had severe consequences on the global economy, environment, public health and social life [1, 2]. Multiple potential vaccines against COVID-19 have been developed swiftly and as shown in several phase 3 clinical trials, they demonstrated considerable efficacy without an unusual safety signal in healthy individuals.ObjectivesIn this study, we aimed to evaluate vaccine reactivity and disease flare following vaccination with either Sinovac/CoronaVac or Pfizer/BioNTech among BS and FMF patients compared with patients with various diagnosis of RD and healthy controls.MethodsOnly those patients and healthy controls who rece,ved at least one single shot of either CoronoVac or BioNTech against COVID-19 were included in the study. We tried to contact all of these patients and controls consecutively by telephone and attempted to make interviews with the eligible ones.ResultsWe studied the efficacy, side effects and disease flares after COVID-19 vaccination in 256 patients with Behcet’s syndrome (BS), 247 with familial Mediterranean fever (FMF), 601 with rheumatic diseases (RD) and 612 healthy controls (HC). Study participants were vaccinated either with CoronaVac (BS:109, FMF: 90, RD: 343, and HC: 334) or BioNTech (BS: 147, FMF:157, RD: 258 and HC: 278). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%; FMF: 3.2% vs 12.2%, RD:2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; RD: 83.3% vs 45.5% and HC: 86.3% vs 52.1%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS:5.5%, FMF:3.3%, RD:2.9% and HC:3.3%) or BioNTech (BS:5.4%, FMF:1.9%, RD:4.7% and HC:4.7%). The main causes for medical assistance were disease flare, and cardiovascular events. Disease flares after vaccination were significantly more frequent among BS (41/256; 16.0%) and FMF (43/247; 17.4%) patients compared to patients with RD (36/601; 6.0%). This was true for both CoronaVac (BS: 11.0%, FMF: 24.4% and RD: 5.2%, p<0.001) and BioNTech (BS: 19.7%, FMF: 13.4% and RD: 7.0%, p=0.001)(Table 1).Table 1.Flares among patients with Behçet’s syndrome, familial Mediterranean fever, rheumatic diseases after vaccination with CoronaVac and BioNTechCoronaVacBehçet’s syndrome,n=109Familial Mediterranean Fever,n=90Rheumatic diseases, n=343Flares, n (%)Flares, n (%)Flares, n (%)12 (11.0)22 (24.4)18 (5.2)BioNTechBehçet’s syndrome, n=147Familial Mediterranean Fever, n=157Rheumatic diseases, n=258Flares, n (%)Flares, n (%)Flares, n (%)29 (19.7)21 (13.4)18 (7.0)RA, Rheumatoid Arthritis; BS, Behçet’s syndrome; FMF, Familial Mediterranean FeverConclusionOur study demonstrates that BS and FMF patients vaccinated with either CoronaVac or BioNTech demonstrated almost similar AE profile and frequency compared to RD patients and HC. AEs that required physician consultation or hospitalization occurred in all study groups after either CoronaVac or BioNTech. Caution should be required when monitoring these patients after vaccination. Increased frequency of flares in BS and FMF compared to that seen in RD might reflect defects in innate immunity and deserves further investigation.References[1]https://covid19.who.int Accessed date 22.01.2022[2]Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R. The so-cio- economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020 Jun; 78:185-193. doi: 10.1016/j.ijsu.2020.04.018. PMID: 32305533; PMCID: PMC7162753.Disclosure of InterestsAyse Ozdede: None declared, Sabriye Güner: None declared, Guzin Ozcifci: None declared, Berna Yurttas: None declared, Zeynep Toker Dincer: None declared, Zeynep Atli: None declared, Ugur Uygunoglu: None declared, Eser Durmaz: None declared, Didar Ucar: None declared, Serdal Ugurlu Speakers bureau: Novartis,Pfizer,Celltrion and Lilly, Sebahattin Saip: None declared, Ömer Fehmi Tabak Speakers bureau: Abbvie, Gilead, MSD and GSK, Consultant of: Abbvie, Gilead, MSD and GSK, Vedat Hamuryudan: None declared, Emire Seyahi Speakers bureau: Pfizer, Abbvie, Novartis and Gilead,
Collapse
|
2
|
Kiral E, Kirel B, Havan M, Keskin M, Karaoglan M, Yildirim A, Kangin M, Talay MN, Urun T, Altug U, Kesici S, Tufan E, Kacmaz E, Bozan G, Azapagasi E, Uysal Yazici M, Ozturk Z, Yesilbas O, Karaguzel G, Kaya G, Barlas U, Duyu M, Boyraz M, Sevketoglu E, Akcay N, Hancili S, Guven A, Dursun O, Ulgen Tekerek N, Ozcifci G, Yazici P, Turanli E, Kendirli T, Kahveci F, Yetimakman AF, Citak A, Şik G, Bingol I, Aygun F, Durak C, Yilmaz R, Bugrul F, Sari Y, Tekguç H, Albayrak H, Yener N, Agin H, Soydan E, Yildizdas D, Dilek SO, Yalindag N, Incekoy-Girgin F, Alacakir N, Tutunculer F, Arslanaoglu MO, Aydin C, Bilgin M, Simsek E, Dinleyici EC. Increased Severe Cases and New-Onset Type 1 Diabetes Among Children Presenting With Diabetic Ketoacidosis During First Year of COVID-19 Pandemic in Turkey. Front Pediatr 2022; 10:926013. [PMID: 35844756 PMCID: PMC9277100 DOI: 10.3389/fped.2022.926013] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 05/31/2022] [Indexed: 12/15/2022] Open
Abstract
INTRODUCTION There have been some significant changes regarding healthcare utilization during the COVID-19 pandemic. Majority of the reports about the impact of the COVID-19 pandemic on diabetes care are from the first wave of the pandemic. We aim to evaluate the potential effects of the COVID-19 pandemic on the severity of diabetic ketoacidosis (DKA) and new onset Type 1 diabetes presenting with DKA, and also evaluate children with DKA and acute COVID-19 infection. METHODS This is a retrospective multi-center study among 997 children and adolescents with type 1 diabetes who were admitted with DKA to 27 pediatric intensive care units in Turkey between the first year of pandemic and pre-pandemic year. RESULTS The percentage of children with new-onset Type 1 diabetes presenting with DKA was higher during the COVID-19 pandemic (p < 0.0001). The incidence of severe DKA was also higher during the COVID-19 pandemic (p < 0.0001) and also higher among children with new onset Type 1 diabetes (p < 0.0001). HbA1c levels, duration of insulin infusion, and length of PICU stay were significantly higher/longer during the pandemic period. Eleven patients tested positive for SARS-CoV-2, eight were positive for new onset Type 1 diabetes, and nine tested positive for severe DKA at admission. DISCUSSION The frequency of new onset of Type 1 diabetes and severe cases among children with DKA during the first year of the COVID-19 pandemic. Furthermore, the cause of the increased severe presentation might be related to restrictions related to the pandemic; however, need to evaluate the potential effects of SARS-CoV-2 on the increased percentage of new onset Type 1 diabetes.
Collapse
Affiliation(s)
- Eylem Kiral
- Pediatric Intensive Care Unit, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Birgul Kirel
- Department of Pediatric Endocrinology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Merve Havan
- Pediatric Intensive Care Unit, Mersin City Hospital, University of Health Sciences, Mersin, Turkey
| | - Mehmet Keskin
- Department of Pediatric Endocrinology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| | - Murat Karaoglan
- Department of Pediatric Endocrinology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| | - Ahmet Yildirim
- Department of Pediatric Endocrinology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
| | - Murat Kangin
- Pediatric Intensive Care Unit, Gazi Yasargil Training and Research Hospital, University of Heath Sciences, Diyarbakir, Turkey
| | - Mehmet Nur Talay
- Pediatric Intensive Care Unit, Gazi Yasargil Training and Research Hospital, University of Heath Sciences, Diyarbakir, Turkey
| | - Tuba Urun
- Pediatric Intensive Care Unit, Gazi Yasargil Training and Research Hospital, University of Heath Sciences, Diyarbakir, Turkey
| | - Umit Altug
- Pediatric Intensive Care Unit, Sanliurfa Training and Research Hospital, University of Heath Sciences, Sanliurfa, Turkey
| | - Selman Kesici
- Pediatric Intensive Care Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - Erennur Tufan
- Pediatric Intensive Care Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey
| | - Ebru Kacmaz
- Pediatric Intensive Care Unit, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Gurkan Bozan
- Pediatric Intensive Care Unit, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Ebru Azapagasi
- Pediatric Intensive Care Unit, Dr Sami Ulus Gynecology Obstetrics and Child Health and Diseases Training and Research Hospital, Ankara, Turkey
| | - Mutlu Uysal Yazici
- Pediatric Intensive Care Unit, Dr Sami Ulus Gynecology Obstetrics and Child Health and Diseases Training and Research Hospital, Ankara, Turkey
| | - Zeynelabidin Ozturk
- Pediatric Intensive Care Unit, Dr Sami Ulus Gynecology Obstetrics and Child Health and Diseases Training and Research Hospital, Ankara, Turkey
| | - Osman Yesilbas
- Pediatric Intensive Care Unit, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
| | - Gulay Karaguzel
- Department of Pediatric Endocrinology, Faculty of Medicine, Karadeniz Technical Universit, Trabzon, Turkey
| | - Gulay Kaya
- Department of Pediatric Endocrinology, Faculty of Medicine, Karadeniz Technical Universit, Trabzon, Turkey
| | - Ulkem Barlas
- Pediatric Intensive Care Unit, Bagcilar Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Muhterem Duyu
- Pediatric Intensive Care Unit, Prof. Dr. Süleyman Yalcin City Hospital, Medeniyet University, Istanbul, Turkey
| | - Merve Boyraz
- Pediatric Intensive Care Unit, Prof. Dr. Süleyman Yalcin City Hospital, Medeniyet University, Istanbul, Turkey
| | - Esra Sevketoglu
- Pediatric Intensive Care Unit, Bakirköy Dr Sadi Konuk Research and Training Hospital, University of Heath Sciences, Istanbul, Turkey
| | - Nihal Akcay
- Pediatric Intensive Care Unit, Bakirköy Dr Sadi Konuk Research and Training Hospital, University of Heath Sciences, Istanbul, Turkey
| | - Suna Hancili
- Department of Pediatric Endocrinology, Zeynep Kamil Women and Children Diseases Traning and Research Hospital, University of Heath Sciences, Istanbul, Turkey
| | - Ayla Guven
- Department of Pediatric Endocrinology, Zeynep Kamil Women and Children Diseases Traning and Research Hospital, University of Heath Sciences, Istanbul, Turkey
| | - Oǧuz Dursun
- Pediatric Intensive Care Unit, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Nazan Ulgen Tekerek
- Pediatric Intensive Care Unit, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Gokçen Ozcifci
- Van Training and Research Hospital, University of Heath Sciences, Van, Turkey
| | - Pinar Yazici
- Pediatric Intensive Care Unit, Ege University Faculty of Medicine, Izmir, Turkey
| | - Eda Turanli
- Pediatric Intensive Care Unit, Ege University Faculty of Medicine, Izmir, Turkey
| | - Tanil Kendirli
- Pediatric Intensive Care Unit, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Fevzi Kahveci
- Pediatric Intensive Care Unit, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Ayse Filiz Yetimakman
- Pediatric Intensive Care Unit, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Agop Citak
- Pediatric Intensive Care Unit, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Guntulu Şik
- Pediatric Intensive Care Unit, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Ibrahim Bingol
- Pediatric Intensive Care Unit, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Fatih Aygun
- Pediatric Intensive Care Unit, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
| | - Cansu Durak
- Pediatric Intensive Care Unit, Selcuk University Faculty of Medicine, Konya, Turkey
| | - Resul Yilmaz
- Pediatric Intensive Care Unit, Selcuk University Faculty of Medicine, Konya, Turkey
| | - Fuat Bugrul
- Department of Pediatric Endocrinology, Selcuk University Faculty of Medicine, Konya, Turkey
| | - Yusuf Sari
- Pediatric Intensive Care Unit, Firat University Faculty of Medicine, Elazig, Turkey
| | - Hakan Tekguç
- Pediatric Intensive Care Unit, Dr. Burhan Nalbantoglu Hospital, Lefkosa, Cyprus
| | - Hatice Albayrak
- Pediatric Intensive Care Unit, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
| | - Nazik Yener
- Pediatric Intensive Care Unit, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey
| | - Hasan Agin
- Pediatric Intensive Care Unit, Dr Behçet Uz Children's Hospital, Izmir, Turkey
| | - Ekin Soydan
- Pediatric Intensive Care Unit, Dr Behçet Uz Children's Hospital, Izmir, Turkey
| | - Dincer Yildizdas
- Pediatric Intensive Care Unit, Cukurova University Faculty of Medicine, Adana, Turkey
| | - Semine Ozdemir Dilek
- Department of Pediatric Endocrinology, Cukurova University Faculty of Medicine, Adana, Turkey
| | - Nilufer Yalindag
- Pediatric Intensive Care Unit, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Feyza Incekoy-Girgin
- Pediatric Intensive Care Unit, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Nuri Alacakir
- Pediatric Intensive Care Unit, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Filiz Tutunculer
- Department of Pediatric Endocrinology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Mehmet Ozgur Arslanaoglu
- Pediatric Intensive Care Unit, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Can Aydin
- Department of Pediatric Endocrinology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Muzaffer Bilgin
- Department of Biostatistics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Enver Simsek
- Department of Pediatric Endocrinology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| | - Ener Cagri Dinleyici
- Pediatric Intensive Care Unit, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
| |
Collapse
|